Analyst Reco. Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
154.2 ^USD	-1.63%		-2.44%	+59.91%

Jun. 26	Monetary policy is getting even more confusing
Jun. 26	Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172	Jun. 26	MT
Citigroup Upgrades Sarepta Therapeutics to Neutral From Buy, Adjusts PT to $176 From $172	Jun. 26	MT
ANALYST RECOMMENDATIONS : Accenture, Chipotle, Rivian, Walmart, Humana...	Jun. 26
Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating	Jun. 24	MT
Evercore ISI Raises Price Target on Sarepta Therapeutics to $185 From $139, Maintains In Line Rating	Jun. 24	MT
BMO Capital Raises Price Target on Sarepta Therapeutics to $200 From $170, Maintains Outperform Rating	Jun. 24	MT
ANALYST RECOMMENDATIONS : Accenture, Walgreens Boots Alliance, Ge Vernova, Pepsico, Britvic...	Jun. 24
Barclays Adjusts Price Target on Sarepta Therapeutics to $226 From $185, Maintains Overweight Rating	Jun. 21	MT
BofA Securities Adjusts Sarepta Therapeutics Price Target to $213 From $166, Maintains Buy Rating	Jun. 21	MT
Oppenheimer Adjusts Sarepta Therapeutics Price Target to $215 From $180, Maintains Outperform Rating	Jun. 21	MT
Needham Raises Price Target on Sarepta Therapeutics to $235 From $166, Maintains Buy Rating	Jun. 21	MT
Baird Raises Sarepta Therapeutics Price Target to $200 From $170, Maintains Outperform Rating	Jun. 21	MT
RBC Raises Price Target on Sarepta Therapeutics to $182 From $142, Maintains Sector Perform Rating	Jun. 21	MT
ANALYST RECOMMENDATIONS : Home Depot, Apple, Micron Technology, Anglo American, United Utilities...	Jun. 21
Sarepta Therapeutics Shares Fall After RBC Downgrade	May. 28	MT
RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Lowers Price Target to $142 From $157	May. 28	MT
Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating	May. 17	MT
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	May. 14	MT
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating	May. 02	MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating	May. 02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Analyst Reco.

Filters